Corneal endothelial dysfunction is the main cause for more than 50% of corneal transplantations. Human corneal endothelial cells are generally viewed as non-proliferative in vivo. Any injury that results in endothelial loss exceeding the critical threshold can cause irreversible endothelial functional decompensation, leading to corneal edema and vision loss. Currently, the mainstay treatment for irreversible corneal dysfunction is corneal transplantation. In this work, using well-established imaging technique of specular microscopy, we revisited the endothelial damage following three common corneal endothelial injury scenarios: post-cataract surgery, endothelial dystrophy, and corneal penetrating injury. We identified unexpected, stochastic single-cell loss in the corneal endothelium following primary injuries, persisting well beyond the expected wound healing period, a phenomenon that has not been previously highlighted. This finding offers a potential explanation for the chronic endothelial cell loss following a primary injury. Further investigation could provide valuable insights for improving clinical management strategies for corneal endothelial dysfunction.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of Chang Gung Medical Foundation gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors